Learning objectives
- Recall current unmet needs in ACS
- Summarise current use of antiplatelet therapy in ACS according to guidelines
- Describe the mode of action of potent P2Y12 inhibitors
- Identify settings where a potent P2Y12 inhibitor should be used in favour of clopidogrel
- Summarise the results of head-to-head trials between clopidogrel and potent P2Y12 inhibitors
- Select appropriate assessment criteria for ischaemic risk and bleeding risk
- Identify patients in whom a medical therapy only approach could be used over invasive strategies
- Use antiplatelet therapy effectively and safely for long-term management of ACS
Faculty
Prof Robert F. Storey
University of Sheffield, UK
University of Sheffield, UK
Prof Roxana Mehran - Panelist
Mount Sinai Hospital, New York, US
Mount Sinai Hospital, New York, US
Prof Dominick J. Angiolillo - Panelist
University of Florida College of Medicine-Jacksonville, US
University of Florida College of Medicine-Jacksonville, US
Prof Kurt Huber - Panelist
Clinic Ottakring, Vienna, AT
Clinic Ottakring, Vienna, AT
